Partner Judy Waltz was quoted in a Bloomberg BNA article, “$729M in Medicare Incentive Payments Deemed Improper,” covering the Office of Inspector General’s payment estimate and how it decided upon that number.
Waltz explained, “The OIG arrived at the $729 million estimate after extrapolating from a much smaller sample, which attorneys have often complained about in the past.”
She also explained that the improper payments report didn’t indicate whether any of the findings had been appealed by health-care providers, so some of the improper payments may turn out to be proper when the appeals are finished.
Click here to view the full article.
Waltz explained, “The OIG arrived at the $729 million estimate after extrapolating from a much smaller sample, which attorneys have often complained about in the past.”
She also explained that the improper payments report didn’t indicate whether any of the findings had been appealed by health-care providers, so some of the improper payments may turn out to be proper when the appeals are finished.
Click here to view the full article.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."